Geno Germano

Geno Germano is a member of the Precision BioSciences Board of Directors and a 30-year veteran of the pharmaceutical and life sciences industry who, prior to joining Elucida Oncology as Chief Executive Officer, served as President of Intrexon, a leader in the application of synthetic biology.

He has held multiple senior roles at major pharmaceutical corporations including Pfizer, Wyeth, and Johnson & Johnson. At Pfizer, he led the Global Innovative Pharmaceutical business, cultivating a $14 billion operation and guiding the development of an extensive portfolio of products in the cardiovascular, immunology, metabolic disease, neuroscience and rare disease areas. He also served as Pfizer’s President and General Manager of the Specialty Care, Vaccines and Oncology business units.

At Wyeth Pharmaceuticals, Mr. Germano served as President of Wyeth U.S., President of the Global Pharmaceutical and Women’s Healthcare business and as Executive Vice President of the Vaccines Business. He has been a member of the Group of Fifty (G50) and served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee. Mr. Germano also previously served on the Advisory Board of the Healthcare Businesswomen’s Association and as a Director of The Medicines Company. He is currently a Director of Sage Therapeutics and Chairman of its Nominating and Governance Committee. He received his Bachelor of Science degree at the Albany College of Pharmacy and Health Sciences.